Abstract
In July 2022, a drug program with CFTR modulators was started at the CF Center in Dziekanow Lesny. Previous observations in other countries have shown that elexacaftor/tezacaftor/ivacaftor (ETI) treatment may be associated with the emotional status in some individuals. The aim of the study was to monitor patients’ emotional condition by assessing the severity of depression and anxiety symptoms.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
